

- Lipoarabinomannan, 1106
 Lipoatrophy, 2430
 Lipodermatosclerosis, 366, 1651
 Lipodystrophy
 in diabetes mellitus, 2422
 familial, 435, 436t, 2450
 forms of, 436e-8f, 2439
 in HIV infection, 1259, 1260f, 1273, 2422, 2450
 lipoprotein disorders in, 2439
 metabolic syndrome and, 2450
 protease inhibitors and, 2422
 treatment of, 2439
 Lipofuscin, 94e-3
 Lipohypertrophy, 2430
 Lipoic acid. *See* α -lipoic acid
 Lipolysis, 1935
 Lipolytic enzymes, 2090
 Lipomas
 cardiac, 289e-2
 clinical features of, 364, 364t
 in MEN 1, 2336t, 2340
 small intestinal, 536
 Lipooligosaccharide (LOS), *N. gonorrhoeae*, 1004
 Lipopeptides. *See* Daptomycin
 Lipopolysaccharide (LPS)
 A. baumannii, 1037
 B. cepacia, 1048
 Brucella, 194e-2, 194e-3
 in inflammatory response, 145e-5, 145e-6f, 1752
 P. aeruginosa, 1043, 1043t
 in septic shock, 1025
 Lipoprotein(a), 1241t, 2436t
 Lipoprotein(s)
 classification of, 1241t, 2435–2437, 2436f
 composition of, 1241t, 2435–2437. *See also*
 High-density lipoprotein (HDL);
 Low-density lipoprotein (LDL); Very-
 low-density lipoproteins (VLDLs)
 metabolism of, 292e-1v
 oxidized, 291e-2
 proteins associated with, 2436–2437
 in transport of dietary lipids, 2437, 2437f
 Lipoprotein disorders
 approach to the patient, **2446**
 arthritis in, 2243
 atherosclerosis and, 291e-4–6, 291e-6t
 cardiovascular disease risk and, 266e-4, 1588
 diagnosis of, 2446
 erectile dysfunction in, 326
 global considerations in, 266e-4
 metabolic causes of
 impaired lipolysis of triglyceride-rich
 lipoproteins, 2439–2440
 primary (genetic), 2439–2440, 2440t
 secondary, 2439
 impaired uptake of LDL, 2440–2441
 primary (genetic), 2441–2443
 secondary, 2441
 low ApoB, 2444–2445. *See also*
 Abetalipoproteinemia (acanthocytosis)
 low HDL-C, 2445–2446, 2451
 very high HDL-C, 2446
 VLDL overproduction, 2438–2439, 2451
 musculoskeletal disorders associated with,
 2242–2243
 screening for
 calculations for, 2446
 classification of results, 480e-3t, 2446
 in elderly, 84
 recommendations, 29t, 2254t
 reference ranges, 480e-3
 secondary causes of, 2444t
 diabetes mellitus, 291e-6, 2428
 drug-related, 2443–2444
 hypothyroidism, 2441
 insulin resistance, 2438, 2450
 kidney disease, 2438–2439, 2441
 liver disease, 2443
 metabolic syndrome, 2451
 obesity, 2438
 pancreatitis, 2091, 2093, 2096
 skin manifestations of, 365
 treatment of, **2446**
 ACC/AHA guidelines for, 291e-4–6,
 291e-6t, 291e-7f
 bile acid sequestrants. *See* Bile acid
 sequestrants
 for cardiovascular disease risk reduction,
 2447
 cholesterol absorption inhibitors, 462e-19,
 2449–2450, 2449t
 fibric acid derivatives. *See* Fibric acid
 derivatives
 high LDL management, 291e-6–7, 291e-8f,
 291e-9f, 2447–2449, 2448t
 LDL apheresis, 2449
 lifestyle modifications, 291e-6, 291e-8t,
 291e-9, 2447
 in metabolic syndrome, 2453–2454
 nicotinic acid. *See* Nicotinic acid
 omega-3 fatty acids. *See* Omega-3 fatty
 acids
 severe hypertriglyceridemia management,
 2446–2447
 statins. *See* Statins
 Lipoprotein glomerulopathy, 1847
 Lipoprotein lipase (LPL), 2450
 Lipoprotein lipase (LPL) deficiency, 91e-3,
 2439–2440, 2440t
 Liposarcoma, 119e-1. *See also* Soft tissue
 sarcoma
 Lipoteichoic acid, 145e-5
 5-Lipoxygenase, 40
 Lip reading, 224
 Liquid nitrogen therapy, 351
 LIR (leukocyte Ig-like receptor), 373e-4
 Liraglutide, 2397, 2414–2415, 2414t
 Lisch nodules, 2343
 Lisfranc fracture–dislocation, 2244
 Lisinopril, 1512t, 1624t
 Lispro, 2411, 2411t
Listeria monocytogenes, 145e-7, 150e-2t, 982,
 982f
Listeria monocytogenes infections
 bacteremia, 983
 in cancer patient, 484t, 486t
 CNS, 983
 complications of, 984
 diagnosis of, 983
 epidemiology of, 982–983
 food-related, 266, 983
 meningitis, 886, 889–890, 889t, 983
 neonatal, 983
 pathogenesis of, 982
 in pregnancy, 983
 prevention of, 984
 prognosis of, 984
 in transplant recipient, 924t, 925, 926
 treatment of, 983–984
 Listeriolysin (LLO), 982
 Lithium
 action of, 465e-2
 adverse effects of
 acid-base disorders, 317
 alopecia, 354
 AV conduction block, 1471t
 common, 2718, 2718t
 cutaneous, 352, 353, 356, 356t, 378
 hypercalcemia, 2475
 lupus syndrome, 2218t
 nail disorders, 380
 nephrogenic diabetes insipidus, 64e-3–4,
 303
 nephropathy, 1856t, 1861–1862
 neuropathy, 2687t
 nystagmus, 211
 obesity, 2392
 psoriasis, 347
 rare, 2718t
 SA node dysfunction, 1467t
 secondary parkinsonism, 2611
 seizures, 2547t
 for bipolar disorder, 2718, 2718t
 for cluster headache prevention, 2595, 2595t
 drug interactions of, 246e-5t
 for hypnic headache, 2598
 overdosage/poisoning with, 473e-12t, 2765t
 pharmacology of, 2718t
 therapeutic monitoring of, 2765t
 Livedoid vasculopathy, 369, 369t
 Livedo reticularis, 68, 369, 1648f, **1649**, 2135
 Liver
 age-related changes in, 94e-4
 alcohol effects on. *See* Alcoholic liver disease
 anatomy of, 366e-1, 366e-1f, 1989–1990
 drug metabolism in, 33–34, 33f
 functions of, 1989–1990
 metastatic tumors to, 553
 ascites with, 287
 colorectal cancer, 542
 NETs, 560, 572–573, 572f
 treatment of, 574
 palpation of, 286
 recellularization of, 92e-2, 92e-3v
 Liver abscess, **850**
 in actinomycosis, 1089, 1090f
 amebic
 clinical features of, 1365
 complications of, 1365
 diagnosis of, 245e-1, 850, 1366, 1366f
 pathogenesis of, 1365
 treatment of, 1367, 1367t
 Candida, 850
 clinical features of, 850
 diagnosis of, 850
 etiology of, 850
 global considerations in, 850
 K. pneumoniae, 850, 1032, 1032f
 treatment of, 850–851
 Liver biopsy, **366e-1**, 1994
 in acetaminophen hepatotoxicity and
 alcoholic liver injury, 366e-4f
 in acute hepatitis, 366e-1f, 366e-6f
 in α_1 -antitrypsin deficiency, 366e-4f
 in autoimmune hepatitis, 366e-2–3f
 in *Brucella* infections, 194e-3, 194e-3f
 in chronic HBV infection, 366e-2f
 in chronic HCV infection, 366e-1–2f,
 366e-3f
 in cirrhosis, 366e-3f
 in cirrhosis secondary to hemochromatosis
 with hepatocellular carcinoma,
 366e-4f
 in CMV infection with liver allograft,
 366e-3f
 contraindications to, 1998
 in hemochromatosis, 366e-4f, 366e-5f, 2517
 in hepatocellular carcinoma, 366e-4f
 indications for, 1996f, 1998
 in NAFLD, 2056
 in nonalcoholic steatohepatitis, 366e-5f
 in primary biliary cirrhosis, 366e-3f
 in primary sclerosing cholangitis, 366e-5f
 in rejection of liver allograft, 366e-3f
 in Wilson's disease, 366e-6f, 2519
 Liver cancer. *See* Hepatocellular carcinoma
 (HCC)
 Liver disease/failure, **1989**. *See also* Cirrhosis
 in alcohol abuse. *See* Alcoholic liver disease
 in α_1 -antitrypsin deficiency, 367e-2, 1992
 in amyloidosis, 367e-3
 in cancer patient, 488, 622
 cholestatic, 283–284, 1990, 1990t, 2060. *See*
 also Biliary cirrhosis
 clinical features of, 286, 1990–1991
 anemia, 631
 ascites, 286, 286f, 1992
 bleeding, 404
 coagulation disorders, 739, 739f, 739t
 cutaneous, 1992–1993
 fatigue, 1991
 halitosis, 242
 hepatomegaly, 1992
 icterus, 1992
 itching, 1991
 jaundice, 283, 1991
 lactic acidosis, 318
 lipoprotein disorders, 2443
 nausea and vomiting, 259, 1991
 neuropathy, 2684